Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novopharm acquisition

This article was originally published in The Tan Sheet

Executive Summary

Teva Pharmaceutical Industries has entered into a letter of intent with Toronto-based Novopharm to acquire the generics firm from Dan Family Holdings for approximately 4.8 mil. Teva shares, the company announces Dec. 2. Based on the day's closing price of 54-1/2, the deal is valued at approximately $261.6 mil. The agreement appears to be contingent on Novopharm selling off its OTC business; the company is finalizing a deal with Leiner Health Products for the sale of its Granutec and Stanley Pharmaceutical subsidiaries (1"The Tan Sheet" Nov. 8, In Brief). The agreement with Leiner is expected to be finalized by year-end, while Teva hopes its Novopharm acquisition can be completed within the next few months

You may also be interested in...

Leiner Health Products

Company to purchase "substantially all of the assets" of Novopharm's Granutec and Stanley Pharmaceuticals divisions under a definitive agreement announced Oct. 25; the transaction is expected to be completed prior to year-end. Both Leiner and Granutec sell private label cimetidine (SmithKline's Tagamet HB). Granutec also began shipping generic ranitidine July 19, a month after Warner-Lambert's Zantac 75 lost its exclusivity. Stanley Pharmaceuticals manufactures and distributes OTCs and vitamin supplements in Canada; Novopharm is based in Toronto

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts